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Background/Aims: The aim of this study was to evaluate 
the eradication rate of a triple therapy regimen that included 
a proton pump inhibitor, amoxicillin, and tetracycline instead 
of clarithromycin in treatment-naïve patients and in patients 
who did not respond to standard triple therapy. Methods: 
This study included 110 patients infected with Helicobacter 
pylori. Patients in groups A and B were treatment-naïve, and 
those in group C were not responsive to previous standard tri-
ple therapy. Patients in group A (n=40) received lansoprazole 
30 mg b.i.d., amoxicillin 1,000 mg b.i.d., and clarithromycin 
500 mg b.i.d. for 14 days. Patients in groups B (n=40) and C 
(n=30) received lansoprazole 30 mg b.i.d., amoxicillin 1,000 
mg b.i.d., and tetracycline 500 mg q.i.d. for 14 days. Results: 
In group A, eradication was achieved in 18 (45%) of the 40 
patients included in the intention-to-treat (ITT) analysis and 
in 18 (47.4%) of the 38 patients included in the per-protocol 
(PP) analysis. In group B, eradication was achieved in 15 
(37.5%) of the 40 patients included in the ITT analysis and in 
15 (39.3%) of the 38 patients included in the PP analysis. In 
group C, eradication was achieved in 14 (46.6%) of the 30 
patients included in the ITT analysis and in 14 (43.8%) of the 
29 patients included in the PP analysis. There was no statis-
tically signiﬁ  cant difference among the 3 groups with regard 
to eradication rates (p>0.05). Conclusions: Despite the low 
rate of resistance to tetracycline, the combination of lanso-
prazole, amoxicillin, and tetracycline instead of clarithromycin 
is not a good option for the eradication of H. pylori. (Gut Liver 
2012;6:41-44)
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INTRODUCTION
Helicobacter pylori is associated with chronic active gastritis, 
peptic ulcer, gastric adenocarcinoma, and mucosa-associated 
lymphoid tissue lymphoma.
1-4 It was accepted as grade 1 car-
cinogen in 1994 by World Health Organization (WHO).
5 While 
the prevalence of H. pylori frequency is decreasing in developed 
countries, it is increasing in developing countries.
6 Although 
“test and treat” is an accepted approach in high prevalence lo-
cations such as Turkey, resistance to antibiotics is an important 
problem and eradication rate is decreasing worldwide.
7 Clini-
cally adequate regimens should provide H. pylori eradication in 
at 80% of patients, and should not cause any important adverse 
effect and clinically significant resistance to antibiotics. The 
most widely accepted standard triple therapy includes amoxicil-
lin, clarithromycin and a proton pump inhibitor (PPI). However, 
eradication rates of this regimen are between 40% and 60%.
8,9 
Resistance to clarithromycin is considered to be the major 
reason for treatment failure. Tetracycline acts via impairing 
ribosome functions similar to clarithromycin.
10 Since resistance 
develops to drug itself not to the action mechanism of the drug, 
we thought that tetracycline could be a good alternative in our 
country where the rate of resistance to clarithromycin is high. 
The aim of this study is to evaluate the eradication rate of triple 
therapy regimen including a PPI, amoxicillin, and tetracycline 
instead of clarithromycin both in treatment-naïve and those 
who did not respond to standard triple therapy.42  Gut and Liver, Vol. 6, No. 1, January 2012
MATERIALS AND METHODS
1. Patients
This prospective, randomized study included 80 treatment-
naïve patients who presented to Haydarpaşa Numune Educa-
tion and Research Hospital Gastroenterology Outpatient Clinic 
with H. pylori-positive nonulcer dyspepsia and 30 patients with 
H. pylori-positive nonulcer dyspepsia who previously did not 
respond to standard triple therapy for 14 days. The presence 
of H. pylori was assessed via histologic examination and rapid 
urease test (CLO
® test) in treatment naive patients. During upper 
gastrointestinal endoscopy, two samples were taken from the 
gastric antrum for histologic assessment and rapid urease test. 
Patients were eligible for the study if both tests were positive 
for H. pylori. The presence of H. pylori was also assessed via the 
same methods in unresponsive patients prior to the previous 
therapy. Unresponsive patients were included into the study by 
confirming H. pylori-positivity with C14 urea breath test 4 to 6 
weeks after completion of therapy. 
Exclusion criteria included a history of treatment for H. py-
lori, upper gastrointestinal surgery, or gastric malignancy, im-
paired liver or renal function, pyloric stenosis, pregnancy, and a 
history of allergy to penicillin or any other antibiotic.
To prevent any interference with H. pylori eradication, pa-
tients that had taken bismuths salts, nonsteroidal antiinflamma-
tory drugs, PPIs, H2 receptor blockers, antibiotics, or probiotics 
within the previous 4 weeks were also excluded. The study pro-
tocol was carried out in accordance with the Helsinki Declara-
tion (2004 revision). All subjects were informed about the study 
protocol and provided written consent. The study protocol was 
approved by the local ethics committee. 
2. Study design
This prospective, randomized study included 110 patients 
infected with H. pylori. Treatment-naïve H. pylori-positive non-
ulcer dyspepsia patients were randomized into group A and B 
according to presenting order (1:1). During the study period, pa-
tients who admitted to outpatient clinic with H. pylori-positive 
nonulcer dyspepsia and did not respond to previous standard 
triple therapy were included in group C.
Patients in group A (n=40) received lansoprazole 30 mg b.i.d. 
plus amoxicillin 1,000 mg b.i.d. plus clarithromycin 500 mg b.i.d. 
(LAC) for 14 days. Patients in group B (n=40) and C (n=30) re-
ceived lansoprazole 30 mg b.i.d. plus amoxicillin 1,000 mg b.i.d. 
plus and tetracycline 500 mg q.i.d. (LAT) for 14 days. 
Patients were asked for any side effects during treatment. 
Patient compliance was evaluated at the end of treatment by 
pill count and was considered good if >80% of the medication 
had been taken. Successful H. pylori eradication was defined as 
a negative 
14C-urea breath test result  4 weeks after discontinua-
tion of therapy.
3. Statistical analysis
All patients were evaluated with intention-to-treat (ITT) anal-
ysis, in which patients without a final H. pylori determination 
or with protocol violations were considered treatment failures. 
Per-protocol (PP) analysis included all subjects that took at least 
80% of the study medication, as prescribed, and completed the 
final H. pylori status assessment. Statistical calculations were 
performed using SPSS version 11.0, 2000 software (SPSS Inc., 
Chicago, IL, USA). Results are presented as mean±standard de-
viation for quantitative variables, and as number and percent-
age for qualitative variables. Student’s t-test and Mann Whitney 
U test were used for evaluation of the differences. Probability 
values less than 0.05 were considered significant.
RESULTS
In all, 110 patients (70 females, 40 males) were analyzed with 
Table 1. Demographic Characteristics of the Patients
Group No.
Age,
mean±SD
Gender, No. 
Male Female
Group A  40   42.7±10.8 13 27
Group B 40 38.5±9.7 15 25
Group C 30   46.5±11.5 12 18
p-value 0.09 0.764
SD, standard deviation.
Table 2. Eradication Rates of the Three Groups
Characteristic 
Group A (LAC)  Group B (LAT)  Group C (LAT)
 p-value
No. ITT/PP, % No. ITT/PP, % No. ITT/PP, %
 Eradication Female 11  40.7/44     8       32/33.3   8  57.1/57.1  
Male   7 53.5/53.5   7 46.6/50   6 42.8/46.6
  Total 18 45/47.4  15   37.5/39.3  14 46.6/48.3  0.7
LAC, lansoprazole 30 mg b.i.d. plus amoxicillin 1,000 mg b.i.d. plus clarithromycin 500 mg b.i.d.; LAT, lansoprazole 30 mg b.i.d. plus amoxicillin 
1,000 mg b.i.d. plus and tetracycline 500 mg q.i.d.; ITT, intention-to-treat; PP, per-protocol.Sezikli M, et al: Tetracycline in Helicobacter pylori Eradication  43
ITT analysis. The patients were randomized into group A (LAC) 
(n=40), group B (LAT) (n=40) and group C (LAT, not respond to 
LAC) (n=30). Demographic characteristics of these 3 treatment 
groups are shown in Table 1. There was no statistically signifi-
cant difference between groups with regard to age and gender 
(p>0.05).
Two patients in group A, 2 patients in group B and 1 patient 
in group C did not return for the post-treatment follow-up. Ac-
cordingly, 38 patients in group A, 38 patients in group B, and 
29 patients in group C were enrolled in the PP analysis. Eradi-
cation rates of 3 groups are shown in Table 2.
One hundred and seven patients completed the study. In 
group A, H. pylori eradication was achieved in 18 (45%) of the 
40 patients included in the ITT analysis and in 18 (47.4%) of 
the 38 patients included in the PP analysis. In group B, H. py-
lori eradication was achieved in 15 (37.5%) of the 40 patients 
included in the ITT analysis and in 15 (39.3%) of the 38 patients 
included in the PP analysis. In group C, H. pylori eradication 
was achieved in 14 (46.6%) of the 30 patients included in the 
ITT analysis, in 14 (43.8%) of the 29 patients included in the 
PP analysis. There was no statistically significant difference 
between 3 groups with regard to eradication rates (p>0.05). The 
relationship between gender and eradication rate was not sig-
nificant (p>0.05). 
The most common side effects were nausea and metallic taste 
in the mouth. Reported side effects were mild and treatment was 
well tolerated. 
DISCUSSION
H. pylori is one of the most important causes in pathophysi-
ology of gastroduodenal diseases. Eradication criteria were 
defined in the Maastricht III report, published by European H. 
pylori Study Group in 2005.
11 Although “test and treat” is an 
accepted approach in high prevalence locations such as Turkey, 
resistance to antibiotics is an important problem and it has been 
reported that H. pylori eradication rate is decreasing throughout 
worldwide.
7,11 Antibiotics used in H. pylori eradication have var-
ious mechanisms of action on the bacteria. Clarithromycin and 
tetracycline works via impairing ribosome functions, whereas 
metronidazole and quinolones work via bacterial DNA and 
RNA. Amoxicillin is destroys the bacterial cell wall. Bismuth 
salts have direct cytotoxic action on the bacteria.
10
While clarithromycin inhibits protein synthesis by binding to 
23S rRNA, tetracycline inhibits protein synthesis by binding to 
16S rRNA of ribosome of the bacteria.
12,13 Clarithromycin has 
been used more intensively than has tetracycline because of 
either its lower minimal inhibitor concentration or easy to use 
and its less frequent adverse effects. Acceptable eradication rates 
(>80%) were achieved with the use of clarithromycin initially; 
however, eradication rate has decreased to 40% over the time 
due to resistance in such locations where unnecessary antibiotic 
use is common.
14,15 In Turkey, the rate of resistance to clar-
ithromycin was 18.7% in 2000,
16 while it reached to 41.9% in 
2009.
17 In an large randomized study performed in our country, 
eradication rate of standard triple therapy including omeprazole 
plus clarithromycin plus amoxicillin for 14 days was found to 
be 43%.
18 A meta-analysis by Kadayifçi et al.
8 revealed that H. 
pylori eradication rate of PPI-based triple therapy regimens was 
84% in 1997 and decreased to 55.3% in 2004. Similar results 
were also reported in studies using a PPI plus amoxicillin plus 
clarithromycin for 1 week. Aydin et al.
19 reported that eradica-
tion rate of this regimen was 93.3% in 1996 and 47.1% in 2004. 
In the present study, we also found eradication rate of stan-
dard triple therapy to be very lower than 80%. To date, there 
is no study combining tetracycline with any agent other than 
metranidazole in the literature. Similarly, eradication rate was 
also low in treatment-naïve patients who received lansopra-
zole plus amoxicillin plus tetracycline. Despite the low rate of 
resistance to tetracycline, eradication rates are lower than ex-
pected probably as a result of that we can not provide sufficient 
antimicrobial concentrations with amoxycillin combination. 
Therefore, we can suggest that tetracycline, which is generally 
preferred in quadruple therapy (a PPI plus metronidazole plus 
tetracycline plus bismuth), is not suitable for combination in 
triple therapy. 
Eradication rates in the group who did not respond to previ-
ous standard triple therapy–similar to naïve patients but far 
from the acceptable rates–is contraversial. Eradication rates in 
studies evaluating patients who did not respond to standard 
triple therapy are various. In a study performed by Matsumoto 
et al.,
20 eradication rates of two different combinations includ-
ing levofloxacin or metronidazole instead of clarithromycin in 
patients unresponsive to previous standard triple therapy were 
73% and 96%, respectively. In another study performed by Perri 
et al.,
21 three different combinations were used in such patients. 
Ranitidine bismuth citrate 400 mg b.i.d. plus amoxicillin 1 g 
b.i.d. plus tinidazole 500 mg b.i.d. (RBCAT) was given to the 
first group, pantoprazole 40 mg b.i.d. plus amoxycillin 1 g b.i.d. 
plus levofloxacin 500 mg once a day to the second group and 
pantoprazole 40 mg b.i.d. plus ranitidine bismuth citrate 240 mg 
b.i.d. plus tetracycline 500 mg q.i.d. plus metronidazole 500 mg 
b.i.d. to the third group. Eradication rates were 85%, 63%, and 
83%, respectively.
Similar to low eradication rate of LAC due to increased rate 
of resistance to clarithromycin, we also achieved low eradica-
tion rates with the use of triple therapy including tetracycline 
instead of clarithromycin despite the low rate of resistance to 
tetracycline. This emphasizes the importance of other factors 
apart from resistance to antibiotics in H. pylori eradication.
In the light of all these results of the previous and our stud-
ies, we can conclude that triple therapy including a PPI plus 
amoxicillin plus tetracycline is not a good option in H. pylori 
eradication despite it has the same mechanism of action with 44  Gut and Liver, Vol. 6, No. 1, January 2012
clarithromycin and very low resistance rate. However, it should 
be noted that the number of patients was low in this study. 
There is need for studies evaluating the efficacy of this regimen 
including large patient groups.
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